Review of GLP-1 drugs for opioid use disorder treatment examines evidence that these peptide drugs modulate reward circuits to reduce opioid craving and use.
Key findingReview of GLP-1 drugs for opioid use disorder treatment examines evidence that these peptide drugs m
What the researchers found
Review of GLP-1 drugs for opioid use disorder treatment examines evidence that these peptide drugs modulate reward circuits to reduce opioid craving and use.
Why it matters
Relevant to peptide therapeutics.
How the study worked
In publication.
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Glucagon-like peptide-1 receptor agonists for the treatment of opioid use disorders: a systematic review.
Acta neuropsychiatrica, 37, e85
Citation
Au, Hezekiah C T; Lam, Pak Ho; Kabir, Fateen; Huang, Chen Lily; Dri, Christine E; Le, Gia Han; Kwan, Angela T H; Wong, Sabrina; Teopiz, Kayla M; McIntyre, Roger S. (2025). Glucagon-like peptide-1 receptor agonists for the treatment of opioid use disorders: a systematic review.. Acta neuropsychiatrica, 37, e85. https://doi.org/10.1017/neu.2025.10038